Superior therapy response predictions for patients with pancreatic cancer (PDAC) using Cellworks Singula: MyCare-009-05

Singula is a superior predictor of PDAC response to therapy compared to Physician Choice. The Singula report can validate therapy selection decision, potentially increasing median PFS and OS and provides alternative therapy selections for non-responders. Prospective validation is needed.